ASV therapy is contraindicated in patients with chronic, symptomatic heart failure (NYHA 2-4) with reduced left ventricular ejection fraction (LVEF ≤ 45%) and moderate to severe predominant central sleep apnoea.
Share this Page
Coronavirus: Stay informed
ResMed is closely monitoring and responding to the COVID-19 pandemic; the health and safety of our people, customers, business partners; and those who use our products and solutions worldwide is our top priority. Read more here.